Let's look at this a different way , Can you show what Enzolytics will actually own ?
enzolytics is selling two subsidiaries what will enzolytics own after this deal is complete
Searching for: Enzolytics subsidiaries deal
Generating answers for you…
Enzolytics, Inc. has executed a binding business combination agreement for the sale of its operating subsidiaries, Biogenysis, Inc. (“BGEN”) and Virogentics Inc. (“VIRO”), to Sagaliam Acquisition Corp (NASDAQ: SAGA) in a transaction valued at $450,000,0001. After this deal, Enzolytics will no longer own these two subsidiaries. However, the specifics of what Enzolytics will own post-deal are not detailed in the sources I found. For the most accurate and up-to-date information, I recommend checking Enzolytics’ official announcements or contacting them directly.
This is what I am coming up with on who filed , this is what came back as the answer below , but for now we have not been told exactly what Enzolytics holds or doesn't . So for now none of us know what exactly Enzolytics actually will retain from this deal. We are all hoping CC carries thru on the original plan of licensing. The below states the same thing the doctor is saying , so is he speaking as Enzolytics or as the company he heads. Keep in mind all the claims were put out 2 years ago under Enzolytics not the subs that is why we invested in this. Nothing is ever clear.
Yes, Enzolytics has filed for patents in their name. The company has proprietary technology for producing fully human Monoclonal Antibodies (mAbs) against infectious diseases1. They have pending international patent applications covering the use of any of its discovered numerous conserved Coronavirus epitopes or conserved HIV epitopes in the production of monoclonal antibodies, the production of vaccines or use in diagnostic tests for detecting the viruses in patients2.
Enzolytics has also filed a comprehensive U.S. and foreign Patent Cooperation Treaty (PCT) Patent Application covering its invention of a novel, innovative technology for improved diagnostics3. They have made progress on their ongoing program to produce Monoclonal Antibodies to treat animals by filing a comprehensive patent application covering its identification of conserved neutralizable epitopes on the Feline Leukemia (FeLV) virus4.
The company’s intellectual property includes issued U.S. Patents covering its technology relating to a peptide that has been demonstrated in clinical trials to provide anti-HIV-1 retroviral benefit in vivo1. They also have pending patent applications covering their anti-HIV monoclonal antibody technology1.
In addition, they have pending patent applications covering the proprietary methodology for producing fully human neutralizing monoclonal antibodies against infectious diseases, including Rabies, influenza A, influenza B, Tetanus, Diphtheria, HIV-2, Anthrax, Smallpox, H1N1 influenza, Herpes Zoster, Varicella Zoster and Ebola1.
Please note that while I strive to provide the most accurate and up-to-date information, it’s always a good idea to check the latest updates from official sources or trusted news outlets.
Learn more
1
enzolytics.com
2
marketscreener.com
3
digitaljournal.com
4
finance.yahoo.com
5
bing.com
6
finance.yahoo.com
7
nasdaq.com
8
ca.finance.yahoo.com
9
seekingalpha.com
did Biogenysis file for patents in their name of the following listed as the company The Company has proprietary technology for producing fully human Monoclonal Antibodies (mAbs) against infectious diseases which is currently being employed to produce Monoclonal Antibody therapeutics for treating the CoronaVirus (SARS-CoV-2), HIV-1 and the Feline Leukemia virus. The Company has also identified conserved epitopes on and has plans to produce mAbs targeting many other viruses, including HIV-2, Influenza A and B, H1N1 influenza, Respiratory syncytial virus (RSV), Small-Pox, Ebola Virus, Tetanus, Diphtheria, HTLV-1/2, Rabies, Herpes zoster, Varicella zoster, Anthrax, Mason-Pfizer monkey virus (MPMV) and Visna virus (VISNA). The Company has also analyzed epitopes of animal viruses and plans to produce mAbs for treating these animal viruses.god
So now if you switch out Enzolytics to Biogenysis this is what you get as an answer
Yes, Biogenysis has filed for patents. The company has proprietary technology for producing fully human Monoclonal Antibodies (mAbs) against infectious diseases123. The pending applications contain 23 separate patent claims covering the 19 discovered highly conserved antigens and epitopes (sites) on the SARS CoV-2 virus123. These include antibodies that bind to the disclosed antigens and epitopes, vaccines based on the antigens, methods of treating, preventing, or reducing the risks of SARS CoV-2 infection with the antigens or binding proteins, and methods and kits for detecting or diagnosing infection by SARS CoV-2 using the antigens or binding proteins123.
Through computer analysis (Artificial Intelligence (AI)), the company discovered 19 immutable conserved virus sites on the COVID-19 virus by analyzing 2.8 million SARS CoV-2 isolates23. These sites are now claimed as patentable based on their novel specificity and the finding that they are conserved on SARS-CoV-223. This is significant because antibodies produced to bind to these conserved, immutable sites can neutralize the virus without the possibility of “virus escape” due to virus mutation23.
However, I couldn’t find specific information about patents related to HIV-1, Feline Leukemia virus, HIV-2, Influenza A and B, H1N1 influenza, Respiratory syncytial virus (RSV), Small-Pox, Ebola Virus, Tetanus, Diphtheria, HTLV-1/2, Rabies, Herpes zoster, Varicella zoster, Anthrax, Mason-Pfizer monkey virus (MPMV) and Visna virus (VISNA). For the most accurate and up-to-date information, I recommend checking the official patent databases or contacting Biogenysis directly.
Learn more
1
benzinga.com
2
finance.yahoo.com
3
accesswire.com
4
bio
